SCHEMBL1941016

SCHEMBL1941016

c1ccc(COc2ccc3c(C4CCCC4)nn(Cc4ccccc4)c3c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 4/20 0.46
CNR2 P34972 4/20 0.46
ACHE P22303 3/20 0.46
DYRK1A Q13627 1/20 0.45
SLC22A12 Q96S37 1/20 0.44
ADORA1 P30542 6/20 0.44
ADORA3 P0DMS8 3/20 0.44
ADORA2A P29274 1/20 0.44
HRH3 Q9Y5N1 3/20 0.43
CYP2D6 P10635 2/20 0.43
HTR3A P46098 1/20 0.42
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
SPHK2 Q9NRA0 2/20 0.41
SPHK1 Q9NYA1 2/20 0.41
S1PR1 P21453 1/20 0.40
PRKX P51817 1/20 0.40
ACVR1 Q04771 1/20 0.40
S1PR5 Q9H228 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1942089 0.99 CNR2 (0.45) CNR1CNR2ACHEDYRK1ASLC22A12
SCHEMBL1940935 0.94 CA12 (0.44) CNR1CNR2ACHEDYRK1ASLC22A12
SCHEMBL1941007 0.86 CNR2 (0.48) CNR1CNR2HRH3NPC1RAB9A
SCHEMBL1940429 0.84 KHK (0.47) DYRK1AHRH3CYP2D6HTR3A
SCHEMBL1939994 0.84 HTR3A (0.53) CNR1CNR2DYRK1AHRH3CYP2D6
SCHEMBL1939148 0.82 SLC22A12 (0.49) CNR2SLC22A12ADORA1ADORA3ADORA2A
SCHEMBL2306802 0.81 SLC22A12 (0.50) CNR1CNR2ACHESLC22A12ADORA1
SCHEMBL1940284 0.80 HRH3 (0.43) DYRK1AHRH3CYP2D6HTR3A
SCHEMBL1939452 0.80 HRH3 (0.43) DYRK1AHRH3CYP2D6HTR3A
SCHEMBL2305598 0.79 L3MBTL1 (0.49) SLC22A12HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173679-B2 Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents LABORATOIRE THERMAMEX (MC) 2012-05-08 US disclosed
US-20110237624-A1 INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS LABORATOIRE THERAMEX (MC) 2011-09-29 US disclosed
CN-101080395-B Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents THERAMEX SAM LAB 2011-08-17 CN disclosed
US-7977364-B2 Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents LABORATOIRE THERMAMEX (MC) 2011-07-12 US disclosed
EP-1812404-B1 INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS THERAMEX (MC) 2011-06-15 EP disclosed
US-20090023779-A1 Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents LABORATOIRE THERAMEX (FR) 2009-01-22 US disclosed
CN-101080395-A Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents THERAMEX (MC) 2007-11-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023779-A1 Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents ESR1, ESR2, GPER1 CNR1 353/4885CNR2 527/4885ACHE 1147/4885
US-20110237624-A1 INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS ESR1, ESR2, GPER1 CNR1 353/4885CNR2 527/4885ACHE 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.